Clara D. Bloomfield

Q: What Schools Are Affiliated With Clara D. Bloomfield

Clara D. Bloomfield is affiliated with the following schools: Humboldt University of Berlin, Ohio State University, University of Minnesota, San Diego State University, University of Chicago, University of Washington, Duke University, University of Münster, University of Helsinki, TU Dresden, Harvard University

Clara D. Bloomfield's AcademicInfluence.com Rankings

Clara D. Bloomfield

Philosophy

#3254

World Rank

#5297

Historical Rank

#1054

USA Rank

Logic

#1041

World Rank

#1663

Historical Rank

#345

USA Rank

philosophy Degrees

Download Badge

Philosophy

Clara D. Bloomfield's Degrees

Doctorate Medicine Harvard University

Why Is Clara D. Bloomfield Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Clara Derber Bloomfield , was an American physician and cancer researcher. Her work focused on the genetic changes that are present in certain types of blood cancers, and how those can be utilized to improve treatment for the affected patients.

(See a Problem?)

Clara D. Bloomfield's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. (1999) (12024)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016) (6707)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. (2009) (4395)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. (1999) (3234)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) (2541)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). (2002) (1610)
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns (2000) (1397)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. (1999) (1331)
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
Acute Myeloid Leukemia. (2015) (900)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. (1990) (807)
Acute myeloid leukaemia (2016) (802)
All-trans-retinoic acid in acute promyelocytic leukemia. (1997) (801)
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. (2009) (751)
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. (1998) (731)
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (720)
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. (2001) (678)
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. (2008) (664)
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? (2007) (584)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. (2006) (508)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. (2005) (501)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. (2008) (487)
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. (1981) (480)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine (2010) (458)
MicroRNA expression in cytogenetically normal acute myeloid leukemia. (2008) (454)
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. (2002) (425)
The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 (2000) (404)
Cytogenetics in acute leukemia (2004) (400)
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. (2012) (386)
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. (2002) (372)
MicroRNA fingerprints during human megakaryocytopoiesis. (2006) (367)
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. (2008) (363)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. (2007) (349)
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. (2000) (346)
Nonrandom chromosome abnormalities in lymphoma. (1983) (338)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (2005) (335)
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. (2010) (333)
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. (2008) (326)
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. (2011) (324)
All patients with acute nonlymphocytic leukemia may have a chromosomal defect. (1981) (323)
Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. (1992) (320)
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. (2001) (318)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2006) (317)
Cytogenetics in acute leukemia. (2004) (315)
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. (1999) (309)
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. (1999) (303)
Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect (1996) (302)
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). (1992) (296)
Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. (1986) (293)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. (2008) (287)
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (2017) (281)
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. (2011) (277)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (274)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. (2011) (270)
The prognostic and functional role of microRNAs in acute myeloid leukemia. (2011) (266)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2008) (266)
Clinical significance of cytogenetics in acute myeloid leukemia. (1997) (266)
Acquired copy number alterations in adult acute myeloid leukemia genomes (2009) (258)
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. (1998) (252)
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. (2003) (250)
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. (2005) (249)
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. (2012) (247)
Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. (1983) (243)
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. (1998) (243)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
ALL-1 partial duplication in acute leukemia. (1994) (237)
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. (2010) (233)
Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. (1975) (232)
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. (1997) (232)
Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). (1997) (231)
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. (2000) (229)
The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. (1998) (226)
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (220)
Clinical importance of cytogenetics in acute myeloid leukaemia. (2001) (219)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. (2003) (215)
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. (1996) (210)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2007) (207)
Expression and prognostic impact of lncRNAs in acute myeloid leukemia (2014) (205)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. (2008) (205)
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. (2001) (204)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. (2004) (202)
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. (1986) (200)
Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation (2007) (199)
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia (2016) (197)
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). (2001) (194)
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (191)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia (2012) (191)
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. (2012) (190)
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. (2008) (190)
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. (2004) (184)
Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia. (1984) (183)
ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. (1994) (182)
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia (2016) (181)
The clinical significance of karyotype in acute myelogenous leukemia. (1989) (181)
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. (2013) (179)
The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes (2009) (177)
BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. (2006) (177)
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. (2005) (176)
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. (2012) (168)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (2017) (166)
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. (2004) (166)
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia (2004) (165)
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. (2007) (165)
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. (1994) (164)
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. (2008) (163)
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (2009) (162)
Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay (1998) (160)
Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 (1993) (159)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia (1994) (156)
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia (2001) (156)
Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia (2013) (155)
Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. (2006) (155)
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. (1996) (153)
Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy (1980) (152)
Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. (1989) (151)
Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. (2003) (146)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. (2005) (142)
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. (2004) (142)
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. (2005) (142)
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. (2013) (141)
11q23 balanced chromosome aberrations in treatment‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † (2002) (141)
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. (2013) (141)
Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. (1994) (141)
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. (1999) (140)
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. (2003) (140)
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. (2005) (139)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. (2008) (139)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
B and T cell lymphomas. Analysis of blood and lymph nodes in 87 patients. (1975) (138)
A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. (1981) (138)
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. (2005) (137)
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. (2006) (136)
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. (2014) (136)
Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics (2005) (136)
Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. (1979) (134)
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. (1997) (131)
Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia. (1983) (130)
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. (2012) (128)
Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant (1982) (127)
Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance (1982) (125)
Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. (1988) (125)
Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia. A study of 28 patients. (1976) (124)
Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B Study (1997) (123)
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. (2001) (122)
Therapy‐related leukemia. A panmyelosis (1979) (120)
Incidence, cytology, and histopathology of non‐Hodgkin's lymphomas in the bone marrow (1974) (120)
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. (1997) (118)
The Philadelphia Chromosome (Ph1) in Adults Presenting with Acute Leukaemia: a Comparison of Ph1+ and Ph1‐ Patients * (1977) (117)
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. (2006) (117)
Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. (1988) (114)
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. (2011) (114)
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (2008) (114)
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (113)
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. (2010) (111)
Long‐term survival of patients with acute myeloid leukemia (1997) (111)
Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia (2001) (110)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (2013) (109)
Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review (2007) (108)
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. (2004) (108)
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. (2007) (107)
The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. (1988) (107)
Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. (1986) (106)
There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas (1985) (106)
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. (2004) (105)
Four new recurring translocations in non-Hodgkin lymphoma. (1989) (105)
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. (2001) (104)
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. (2013) (103)
Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. (1985) (103)
There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. (1985) (101)
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. (2007) (100)
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies (2006) (100)
Chromosomal abnormalities in acute lymphoblastic leukemia. (1981) (96)
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
Targeting Leukemia Stem Cells in vivo with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia (2015) (93)
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. (2007) (92)
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma (2004) (92)
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia (2008) (91)
Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances (2007) (91)
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. (2001) (90)
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) (2014) (90)
Report of the Committee on Chromosome Rearrangements in Neoplasia and on Fragile Sites. (1985) (90)
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010) (88)
Chromosome abnormalities in acute nonlymphocytic leukemia: clinical and biologic significance. (1987) (88)
Myelodysplastic syndromes clinical practice guidelines in oncology. (2006) (87)
Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. (1992) (86)
Banded chromosome analysis in patients with treatment-associated acute nonlymphocytic leukemia. (1984) (85)
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. (2012) (85)
ras oncogene activation and occupational exposures in acute myeloid leukemia. (1992) (85)
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. (2008) (84)
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. (2014) (84)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. (1997) (84)
Introduction: acute leukemia: recent advances. (1997) (83)
BAALC, a novel marker of human hematopoietic progenitor cells. (2003) (79)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. (1994) (77)
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies (2018) (76)
Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B (2004) (76)
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. (2012) (76)
Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction. (1978) (75)
Multivariate analysis of prognostic factors in the non‐Hodgkin's malignant lymphomas (1974) (75)
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. (2018) (72)
Acute monoblastic leukemia: diagnosis and treatment of ten cases. (1975) (72)
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia (2009) (71)
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. (2008) (71)
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes (2003) (70)
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia (2014) (69)
PROGNOSTIC SIGNIFICANCE OF LYMPHOCYTE SURFACE MARKERS IN ADULT NON-HODGKIN'S MALIGNANT LYMPHOMA (1976) (69)
Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry (1998) (68)
Nodular lymphoma: Bone marrow and blood manifestations (1975) (68)
Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B (1980) (68)
IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA (1980) (67)
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). (2009) (66)
Effect of age on therapeutic response and survival in advanced Hodgkin's disease. (1982) (66)
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. (2012) (65)
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. (2011) (65)
Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. (2000) (64)
B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease. (1973) (64)
Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene (1999) (63)
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. (2001) (63)
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia (2015) (63)
Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. (1998) (63)
Combination versus successive single agent chemotherapy in lymphocytic lymphoma (1978) (62)
Treatment of acute nonlymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy (1977) (62)
Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications (1999) (62)
Glucocorticoid receptors in adult acute lymphoblastic leukemia. (1981) (62)
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia (2017) (61)
PROLONGED MAINTAINED REMISSIONS OF ADULT ACUTE NON-LYMPHOCYTIC LEUKAEMIA (1977) (60)
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype (2014) (60)
Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology (2000) (58)
Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. (2000) (58)
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. (2002) (57)
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. (2013) (57)
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine (2003) (57)
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia (2013) (57)
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia (2013) (57)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) (2016) (56)
Long-term disease-free survival in acute nonlymphocytic leukemia. (1981) (56)
THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi ﬁ cation of myeloid neoplasms and acute leukemia (2016) (56)
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study (2019) (56)
Glucocorticoids and lymphocytes. III. Effects of glucocorticoid administration on lymphocyte glucocorticoid receptors. (1983) (55)
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. (2021) (55)
Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. (1993) (55)
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. (2014) (55)
Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia (1980) (54)
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. (2002) (54)
Translocation t(12;22)(q13;q12.2–12.3) in a clear cell sarcoma of tendons and aponeuroses (1993) (53)
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. (2017) (53)
The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia (2019) (53)
Morphology of chronic lymphocytic leukemia and its relationship to survival. (1975) (53)
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia (2015) (53)
The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. (1997) (52)
B-cell markers on lymphoblasts in acute lymphoblastic leukaemia. (1974) (52)
Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. (1996) (52)
Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. (2008) (52)
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years (2020) (52)
Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia (2016) (52)
Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. (1996) (51)
Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. (1998) (51)
Recurring chromosome abnormalities in Hodgkin's disease (1992) (50)
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. (2011) (50)
Molecular signatures in acute myeloid leukemia (2009) (49)
FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia (2007) (49)
MicroRNA expression in acute myeloid leukemia (2009) (49)
5-Azacytidine and renal tubular dysfunction. (1981) (49)
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. (1982) (49)
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy (2013) (48)
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. (2013) (48)
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. (2007) (48)
Chromosome abnormalities in secondary myelodysplastic syndromes. (2009) (47)
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. (2012) (47)
An altered 11-kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation. (1992) (46)
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically (2019) (46)
Morphologic and cytochemical characteristics of acute promyelocytic leukemia (1989) (46)
Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia (1986) (46)
Trisomy 13 in acute leukemia. (1992) (46)
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia (2016) (46)
Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB study (1995) (45)
t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic- clinicopathologic association (1985) (45)
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. (2014) (44)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
Time to repeal and replace response criteria for acute myeloid leukemia? (2018) (44)
Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. (1992) (44)
Prognostic significance of the Philadelphia chromosome in acute lymphocytic leukemia (1980) (44)
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced‐stage disease (1993) (43)
Predictability of immunologic phenotype of malignant lymphomas by conventional morphology. A study of 60 cases (1979) (43)
changes of myeloid neoplasms and acute leukemia: rationale and important The 2008 revision of the World Health Organization (WHO) classification (2013) (43)
Significance of Haematological Parameters in the Non‐Hodgkin's Malignant Lymphomas (1976) (42)
Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. (1989) (42)
Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. (1997) (42)
Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 (2014) (42)
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO (2016) (42)
Multidrug resistance in acute myeloid leukemia. (1991) (42)
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 (2016) (42)
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. (2013) (41)
Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia. (1992) (41)
Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance. (1982) (41)
Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells (2019) (41)
Low cancer incidence rates in Ohio Amish (2009) (40)
Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) (2014) (40)
Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats (2008) (40)
Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia (2010) (40)
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. (2011) (39)
Sister chromatid exchange in patients with viral disease. (1978) (39)
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials (2013) (39)
Use of monoclonal antibodies, morphology, and cytochemistry to probe the cellular heterogeneity of acute leukemia and lymphoma. (1981) (38)
Correlations between immunological phenotype and karyotype in malignant lymphoma. (1986) (38)
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. (1995) (38)
Glucocorticoid receptors in leukemia and lymphoma. (1984) (37)
Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3. (1993) (37)
Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines (2015) (37)
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia (2017) (37)
Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. (2005) (36)
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. (2002) (36)
Monoclonal antibody MCS-2 as the marker of phorbol diester-induced myeloid differentiation in acute undifferentiated leukemia. (1984) (36)
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia (2017) (36)
Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. (1984) (35)
The revised French-American-British classification of acute myeloid leukemia: is new better? (1985) (35)
Cytochemical profiles in acute lymphoblastic leukemia (1979) (35)
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss‐of‐function mutations (2005) (35)
Granulocyte Transfusion: A Controlled Study in Patients with Acute Nonlymphocytic Leukemia (2003) (35)
Family history of cancer and incidence of acute leukemia in adults. (2002) (34)
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. (2013) (34)
Controversies in transfusion medicine (1992) (34)
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification (2014) (34)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia. (1990) (34)
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. (2004) (34)
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia (2016) (33)
Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. (1988) (33)
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A (2020) (33)
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. (2006) (33)
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804 (2009) (32)
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. (2020) (32)
Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience. (2005) (32)
Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literature. (1998) (32)
Bone marrow involvement in Burkitt's lymphoma (1977) (32)
Risk of adult acute leukemia in relation to prior immune-related conditions. (1996) (32)
Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy. (1987) (32)
The role of radiation therapy in the treatment of early stage large cell lymphoma (1985) (32)
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. (2010) (32)
Relationship of Clinical Staging and Lymphocyte Morphology to Survival in Chronic Lymphocytic Leukaemia (1980) (31)
Molecular cytogenetic characterization of the KG‐1 and KG‐1a acute myeloid leukemia cell lines by use of spectral karyotyping and fluorescence in situ hybridization (2003) (31)
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) (2004) (31)
Post-remission therapy in acute myeloid leukemia. (1985) (31)
Nosocomial septicemia in the cancer patient: the influence of central venous access devices, neutropenia, and type of malignancy. (1990) (31)
B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy. (1976) (31)
Myelodysplastic syndromes, version 2.2015. (2015) (31)
Acute granulocytic leukemia in elderly patients. (1973) (30)
Curative radiotherapy for localized diffuse histiocytic lymphoma. (1980) (30)
The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses. (1981) (30)
Morphologic and cytochemical characterization of adult lymphoid leukemias which express myeloid antigen. (1988) (30)
Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study (1998) (30)
Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study (2013) (30)
MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. (2009) (30)
Band 11 q 13 is nonrandomly rearranged in hibernomas (1994) (30)
Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-d-aspartate 2C receptor subunits (2007) (29)
FAB M7: acute megakaryoblastic leukemia--beyond morphology. (1985) (29)
The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. (2001) (29)
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia (2017) (29)
Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction (1978) (29)
The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. (1984) (28)
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. (2006) (28)
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. (1997) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 (2011) (28)
Daunorubicin‐prednisone remission induction with hydroxyurea maintenance in acute non‐lymphocytic leukemia (1973) (28)
Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study (2009) (28)
Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. (1997) (28)
t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association. (1985) (28)
Myelodysplastic syndromes: clinical practice guidelines in oncology. (2013) (28)
Prognostic factors at relapse for adults with acute myeloid leukemia (1990) (27)
Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. (1987) (27)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome (2018) (27)
Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma. (1977) (27)
Sequential karyotypes in non‐Hodgkin lymphoma: Their nature and significance (1990) (27)
Hypocellular acute leukemia. (1982) (27)
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study (1995) (26)
Clinical and functional significance of circular RNAs in cytogenetically normal AML. (2020) (26)
Chromosome abnormalities in peripheral T‐cell lymphoma (1987) (26)
Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. (2007) (26)
Cytogenetic studies of 21 patients with acute lymphoblastic leukemia in relapse. (1989) (26)
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 (2014) (26)
Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases. (1977) (26)
Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808 (2013) (26)
Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT–PCR useful clinically? (2003) (26)
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (26)
Analysis of activated and nonactivated cytoplasmic glucocorticoid-receptor complexes from human leukemia cells by rapid DNA-diethylaminoethyl minicolumn chromatography. (1983) (26)
Glucocorticoid receptors and in vitro responses to glucocorticoid in acute nonlymphocytic leukemia. (1981) (25)
A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808. (2005) (25)
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia (2012) (25)
Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. (1991) (25)
Tobacco use among the Amish in Holmes County, Ohio. (2008) (25)
Surface markers define human lymphoid malignancies with differing prognoses. (1977) (24)
Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy. (1990) (24)
A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non‐Hodgkin's lymphomas cancer and leukemia group B study 7851 (1990) (24)
DIVERSITY OF PHENOTYPES OF NON-HODGKIN'S MALIGNANT LYMPHOMA (1982) (24)
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation (2014) (24)
The role of heredity in cancer. (1989) (24)
Daunorubicin-prednisone treatment of erythroleukemia. (1974) (24)
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study (2011) (24)
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. (1992) (24)
Cyclophosphamide, doxorubicin, vincristine, and low‐dose continuous infusion bleomycin in non‐Hodgkin's lymphoma: Cancer and leukemia group B study #7804 (1982) (24)
Abstracts of workshop presentations (Part 13 of 13) (1985) (23)
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. (2004) (23)
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia (2012) (22)
Acute leukemia and residential proximity to potential sources of environmental pollutants. (1993) (22)
Acute nonlymphocytic leukemia in patients with nodular lymphoma (1977) (22)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Der(16)T(1-16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia-chromosome-positive acute lymphoblastic-leukemia. (1995) (21)
15;17 Translocation in acute promyelocytic leukemia. (1982) (21)
High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. (1993) (21)
Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway (2014) (21)
Prognostic implications of cytology in acute leukemia in the adult: the case for subacute leukemia. (1974) (21)
Sister chromatid exchange in lymphocytes from patients with malignant lymphoma (1978) (21)
Treatment of adult acute nonlymphocytic leukemia--1980. (1980) (21)
Chronic and Acute Leukemias in Adults (2012) (21)
Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation (2017) (21)
Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. (2017) (21)
Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. (1997) (21)
Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102). (2005) (20)
Abstracts of workshop presentations (Part 2 of 16) (1987) (20)
Secondary myelodysplastic syndromes and leukaemias. (1986) (20)
Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia? (2003) (20)
Stabilization of labile glucocorticoid-receptor complexes from acute nonlymphocytic leukemia cells by a factor from chronic lymphocytic leukemia cells. (1984) (20)
Report of the committee on structural chromosome changes in neoplasia. (1987) (19)
Re-induction of complete remissions in adults with acute non-lymphocytic leukemia. (1981) (19)
Cancer screening practices among Amish and non-Amish adults living in Ohio Appalachia. (2011) (19)
Abstracts of workshop presentations (Part 6 of 16) (1987) (19)
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance) (2013) (19)
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461 (2013) (19)
In vitro glucocorticoid studies in human lymphoma: clinical and biologic significance. (1981) (19)
Response of therapy-associated acute nonlymphocytic leukemia to intensive induction chemotherapy. (1985) (19)
Daunorubicin therapy in adult acute lymphatic leukemia (1972) (18)
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (2004) (17)
MuCor: mutation aggregation and correlation (2015) (17)
Health Literacy Among the Amish: Measuring a Complex Concept Among a Unique Population (2013) (17)
Complementary and Alternative Medicine Use Among Amish and Non-Amish Residents of Ohio Appalachia (2009) (17)
Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line. (2002) (17)
Liver irradiation in stage IIIA Hodgkin's disease patients with splenic involvement (1984) (17)
High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia. (1978) (16)
Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. (2006) (16)
Expression of the CD15 antigen on normal and leukemic myeloid cells: effects of neuraminidase and variable detection with a panel of monoclonal antibodies. (1991) (16)
The proportion of mitoses in different cell lineages changes during short-term culture of normal human bone marrow. (1986) (16)
Hodgkin disease/lymphoma. (2008) (16)
Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project. (1990) (15)
Covalent labeling of rat thymocyte and human lymphoid glucocorticoid receptor. (1983) (15)
Dietary Intake, Food Processing, and Cooking Methods Among Amish and Non-Amish Adults Living in Ohio Appalachia: Relevance to Nutritional Risk Factors for Cancer (2011) (15)
Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12;21)), 27-28 June 1997, Rotterdam, The Netherlands. (1997) (15)
Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions (2006) (15)
Radical radiation therapy in the treatment of laparotomy staged Hodgkin's disease patients (1984) (15)
Glucocorticoid receptors in chronic lymphocytic leukemia. (1985) (15)
Physical Activity Among Amish and Non-Amish Adults Living in Ohio Appalachia (2012) (15)
Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit) (2018) (15)
Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia (2019) (15)
VP 16-213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features. (1981) (14)
UBASH 3 B / Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML 1 - (2015) (14)
Bone marrow cytogenetics: the lineage of dividing cells changes during the first few hours in culture. (1987) (14)
Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 (2003) (14)
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2 (2016) (14)
Der(16)t(1;16) is a secondary chromosome aberration in at least eighteen different types of human cancer (1998) (14)
Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. (1998) (14)
Extended field radiotherapy in non-Hodgkin's lymphoma. (1976) (14)
Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages. (1989) (14)
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851. (1987) (13)
Glucocorticoid receptor levels predict response to treatment in human lymphoma. (1984) (13)
Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality (2001) (13)
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA (2018) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
Treatment of Biologically Determined Subsets of Acute Lymphoblastic Leukemia in Adults: Cancer and Leukemia Group B Studies (1997) (13)
Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance) (2016) (13)
Abstracts of workshop presentations (Part 1 of 13) (1985) (13)
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). (2021) (13)
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 (2017) (13)
Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia (2017) (13)
Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. (2017) (13)
G3139, a BCL-2 antisense oligo-nucleotide, in AML. (2004) (12)
Introduction: Acute Myeloid Leukemia (2008) (12)
Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study (2008) (12)
VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas. (1980) (12)
Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour (1996) (12)
High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) (2008) (12)
Immunophenotyping in the diagnosis and classification of acute lymphoblastic leukemia. (1988) (12)
Long‐term survival of patients with acute myeloid leukemia (1997) (12)
Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation (2016) (12)
Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. (2021) (12)
Benchmarks in clinical productivity: a national comprehensive cancer network survey. (2007) (12)
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (2019) (11)
Cytogenetics and oncogenes in leukemia (1992) (11)
Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. (2016) (11)
Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study (2015) (11)
Cytogenetics of non-Hodgkin's lymphoma. (1990) (11)
Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome (2013) (11)
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) (2012) (11)
Cytogenetics of indolent lymphomas. (1993) (11)
Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. (2005) (11)
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107 (2008) (11)
Abnormal immunoregulation in patients with non-Hodgkin's malignant lymphomas. I. Increased helper function of peripheral blood T lymphocytes. (1982) (11)
Acute leukemia as a terminal event in nonleukemic hematopoietic disorders. (1976) (11)
Clinical significance of the cytogenetics of acute leukemias. (1990) (10)
Abstracts of workshop presentations (Part 9 of 13) (1985) (10)
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. (2021) (10)
Double Esterase Staining andOther Neutrophilic Granule Abnormalities in 237 Patients with the Myelodysplastic Syndrome Studied by the Cancer and Leukemia Group B (1998) (10)
The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma. (1981) (10)
No evidence for microsatellite instability in acute myeloid leukemia (2017) (10)
Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone. (1981) (10)
Abstracts of workshop presentations (Part 12 of 16) (1987) (10)
Uncommon patterns of presentation of leukemia (1999) (10)
The Clinical Relevance of Lymphocyte Surface Markers in Adult Acute Lymphoblastic Leukemia (1982) (10)
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). (2021) (9)
High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults (2015) (9)
Abstracts of workshop presentations (Part 12 of 13) (1985) (9)
DNA nucleotidylexotransferase of normal persons and leukemic patients. (1980) (9)
Group B studies A comparison of Children's Cancer Group and Cancer and Leukemia acute lymphoblastic leukemia treated on cooperative group protocols? What determines the outcomes for adolescents and young adults with (2011) (9)
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline (2013) (9)
Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia (2013) (8)
Myelodysplastic SyndromesPractice Guidelines in Oncology (2011) (8)
Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study (2010) (8)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461 (2004) (8)
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) (2015) (8)
The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis. (2007) (8)
Association of partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute non-lymphocytic leukemia. (1983) (8)
Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes (2021) (8)
Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia (2019) (8)
Results of lung irradiation for Hodgkin's disease patient with large mediastinal masses and/or hilar disease. (1982) (8)
Abstracts of workshop presentations (Part 15 of 16) (1987) (8)
The Use of Daily Aspirin, Nutritional Supplements and Alternative Medications among Amish and non-Amish living in Ohio Appalachia (2012) (8)
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) (2016) (8)
Radical treatment of Hodgkin disease with radiation therapy: results of a 15-year clinical trial. The 1985 Erskine lecture. (1987) (8)
Round cell liposarcoma with the insertion (12;16)(q13;p11.2p13). (1997) (8)
Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/ Cancer and Leukemia Group B (CALGB) Study. (2009) (8)
The effects of glucocorticoid therapy on glucocorticoid receptors in leukemia and lymphoma (1981) (8)
Adult Leukemias 1 (1982) (8)
New recurrent structural chromosome aberrations in non-Hodgkin's lymphoma. (1996) (7)
Trisomy 13: A New Recurring Chromosome Abnormality in Acute Leukemia (1990) (7)
Phenotypes of Adult Acute Lymphoblastic Leukemia Defined by Monoclonal Antibodies (1984) (7)
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99. (2004) (7)
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia (2021) (7)
The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells. (1992) (7)
Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults (1994) (7)
The clinical relevance of lymphocyte surface markers in leukemia and lymphoma. (1980) (7)
Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652. (1990) (7)
Association of partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute non-lymphocytic leukemia [letter] (1983) (7)
The clinical significance of biological characteristics of the cells in acute myeloid leukemia. (1991) (7)
Granylocyte transfusion: a controlled study in patients with acuute nonlymphocytic leukemia. (1975) (7)
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan (2009) (7)
Abstracts of workshop presentations (Part 10 of 16) (1987) (7)
Large mediastinal masses in Hodgkin's disease: Comparison of the results of whole lung and regular mantle field irradiation (1979) (7)
Acute myeloid leukemia. Introduction. (2008) (7)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). (2009) (6)
Serum and urine glycosaminoglycans in myeloid leukemia and myelodysplasia. (1989) (6)
Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129 (2011) (6)
Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts) (2011) (6)
Chromosome abnormalities in malignant lymphoma: biologic and clinical correlations. (1985) (6)
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement (2021) (6)
Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study (2007) (5)
Myelodysplastic syndromes. (2011) (5)
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. (2004) (5)
Clinical importance of genetic findings in adult AML (2002) (5)
Predictive value of flow cytometric analyses of blast cells in assessing the phenotype of the leukemia colony-forming cell (L-CFC) population in acute myeloid leukemia. (1992) (5)
The clinical use of cytogenetics in acute leukemia. (1991) (5)
5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study. (1982) (5)
Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24 (1992) (5)
Treatment of adult acute nonlymphocytic leukemia--1978. (1978) (5)
Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102). (2007) (5)
Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia (2019) (5)
Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance) (2020) (5)
Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001. (2007) (5)
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. (2009) (5)
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) (2012) (5)
Evaluation of leukemic cell chromosomes as a guide to therapy. (1982) (5)
CHROMOSOMAL ABNORMALITIES IN NON-HODGKIN'S MALIGNANT LYMPHOMA11This work was supported by the Coleman Leukemia Research Fund and by NCI grant 17034. (1982) (4)
Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure (2020) (4)
Pre-Treatment Cytogenetics Predict Complete Remission and Long-Term Outcome in Patients (Pts) ≥60 Years with Acute Myeloid Leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (4)
PML-RARα isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia (APL). (2006) (4)
miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53 (2014) (4)
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). (2016) (4)
Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia. (1990) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21 (2019) (4)
Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. (2009) (4)
Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710 (2007) (4)
High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal acute myeloid leukemia (CN AML): A Cancer and Leukemia Group B (CALGB) study (2007) (4)
Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen‐year follow‐up results (1988) (4)
Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. (2007) (4)
HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia (2016) (4)
FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) (2018) (4)
Abstracts of workshop presentations (Part 3 of 16) (1987) (4)
Abstracts of workshop presentations (Part 7 of 16) (1987) (4)
Abstracts of workshop presentations (Part 1 of 16) (1987) (4)
HÆMOCHROMATOSIS AND ANTHRACYCLINES: FREE-RADICAL-MEDIATED TISSUE INJURY? (1978) (3)
Management of patients with acute non-lymphocytic leukemia who fail first cycle of induction therapy. (1981) (3)
Central Review of Cytogenetics Is Essential for Cooperative Group Clinical and Correlative Studies of Acute Leukemia: The Cancer and Leukemia Group B (CALGB) 8461 Experience. (2004) (3)
Acute non-lymphocytic leukemia. (1979) (3)
ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable9 Genetic Category (2011) (3)
Laparotomy in the re-evaluation of patients with advanced Hodgkin's disease. (1981) (3)
Golub , Monitoring and Class Prediction by Gene Expression Molecular Classification of Cancer : Class Discovery (2007) (3)
A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485 (2016) (3)
A precision medicine classification for treatment of acute myeloid leukemia in older patients (2021) (3)
The Clinical Usefulness of Chromosome Abnormalities in Acute Leukemia (1985) (3)
Abstracts of workshop presentations (Part 4 of 16) (1987) (3)
Daunorubicin-prednisone in the treatment of acute nonlymphocytic leukemia. (1981) (3)
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902. (1988) (3)
Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720). (2006) (3)
Response: Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myeloid leukemia (CN-AML) might be related to many factors, including techniques used to detect FLT3-TKD, differences in patient populations studied, and treatment regimens (2008) (3)
Acute myeloid leukemia with adverse cytogenetic risk. (2012) (3)
Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). (2007) (3)
CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights. (2006) (3)
Acute myeloid leukaemia in 2012: En route to improved treatment options (2013) (3)
Abstracts of workshop presentations (Part 11 of 13) (1985) (3)
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
Abstracts of workshop presentations (Part 8 of 16) (1987) (3)
Chapter 14 – NITROSOUREAS IN THE THERAPY OF HODGKIN'S DISEASE (1981) (3)
Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study (2005) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
High BAALC Expression as an Independent Adverse Risk Factor in 309 Patients with Acute Myeloid Leukemia (AML) and Normal Cytogenetics: Results of the SHG’96 Study. (2004) (2)
Abstracts of workshop presentations (Part 5 of 16) (1987) (2)
Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma (2004) (2)
Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias (2010) (2)
Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). (2005) (2)
Abstracts of workshop presentations (Part 4 of 13) (1985) (2)
tyrosine kinase genes of patients with de novo acute myeloid leukemia Somatic mutations and germline sequence variants in the expressed (2013) (2)
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105. (2006) (2)
Vinblastine, procarbazine, and cytosine arabinoside in combination for reinduction of childhood acute myelocytic leukemia. (1976) (2)
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (2)
FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study (2007) (2)
Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2018) (2)
The clinical significance of chromosomal changes in acute leukemia. (1985) (2)
Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia. (1992) (2)
Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q). (2004) (2)
Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia. (2005) (2)
marrow and acute leukemia cells receptors defined by murine monoclonal antibodies on normal bone Expression of the three myeloid cell-associated immunoglobulin G Fc (2011) (2)
Abstracts of workshop presentations (Part 11 of 16) (1987) (2)
Prolonged disease-free survival in adult acute non-lymphocytic leukemia (ANLL) (1979) (2)
Autologous bone marrow transplantation in non-Hodgkin's lymphoma (1988) (2)
The clinical significance of chromosomal changes in childhood acute leukemia (1985) (2)
A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification (2018) (2)
Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein (2008) (2)
Abstracts of workshop presentations (Part 14 of 16) (1987) (2)
Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001 (2011) (2)
Lymphography as a guide during laparotomy in Hodgkin's and non-Hodgkin's lymphomas. (1977) (2)
Characteristics, stability and regulation of glucocorticoid-receptor complexes in normal and neoplastic cells as studied with a new mini-column technique. (1984) (2)
Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. (2006) (2)
SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML) (2012) (2)
prognostically prioritized molecular classification ? acute myeloid leukemia with normal cytogenetics : are we ready for a Clinical relevance of mutations and gene-expression changes in adult (2006) (2)
An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups. (2007) (2)
Genomic DNA Copy Number Alterations Present in AML Bone Marrow Samples with Normal Cytogenetics. (2004) (2)
First Meeting on Acute Leukemias with structurally altered core binding factor subunits (1997) (2)
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study (2010) (2)
Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL)-Preliminary results of CALGB 10001. (2006) (2)
Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study. (2009) (2)
Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804. (1982) (2)
Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16) (2011) (1)
Have cancer cytogeneticists been wrong in assigning chromosome 12 breakpoints in benign tumors? (1996) (1)
Nonrandom Chromosome Abnormalities in Lymphoma 1 (2006) (1)
Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia (2015) (1)
Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. (2006) (1)
Group B Study 9222 myeloid leukemia in adults under 60 years of age: Cancer and Leukemia cytarabine alone as postremission intensification therapy for acute Sequential multiagent chemotherapy is not superior to high-dose (2013) (1)
Chromosome Abnormalities in Acute Myeloid Leukaemia and Their Clinical Importance (2015) (1)
Low Incidence of TALl Gene Rearrangements in Adult Acute Lymphoblastic Leukemia : A Cancer and Leukemia (2005) (1)
Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia (2015) (1)
Abstracts of workshop presentations (Part 7 of 13) (1985) (1)
Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461. (2004) (1)
Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML) (2018) (1)
B 8461 older with acute myeloid leukemia: results from cancer and leukemia group complete remission and long-term outcome in patients 60 years of age or Pretreatment cytogenetics add to other prognostic factors predicting (2011) (1)
Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia (2018) (1)
Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)–An International Study (2011) (1)
Therapy of Hodgkin's disease (HD) with cyclophosphamide, vinblastine, procarbazine, prednisone (CVPP): 5 year follow-up (1979) (1)
All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia (2001) (1)
Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand? (2019) (1)
High Dose Cytosine Arabinoside, Idarubicin and G-CSF Therapy for De Novo and Secondary Adult Acute Myeloid Leukemia (1992) (1)
The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment (2019) (1)
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study (2018) (1)
Banded chromosome abnormalities in non-Hodgkin’s lymphoma. Correlations with morphology, immunologic phenotype and clinical course (1985) (1)
Cycochemical profiles in acute lymphoblastic leukemia. (1979) (1)
Abstracts of workshop presentations (Part 9 of 16) (1987) (1)
Abstract 2717: Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study (2010) (1)
Translocation 4 ; ! ! in Acute Lymphoblastic Leukemia : Clinical Characteristics and Prognostic Significance (2005) (1)
High expression of the transcription factor ERG predicts unfavorable outcome in acute T-lymphoblastic leukemia (T-ALL) in adults. (2006) (1)
Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged <60 Years: An Analysis of Alliance for Clinical Trials in Oncology (Alliance) Studies (2018) (1)
Result of curative radiation therapy in surgically staged hodgkin's disease — 10 years experience at University of Minnesota experience from 1970 to 1979 (1980) (1)
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations (2020) (1)
The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts) (2012) (1)
Genetics in the management of adult de novo AML. (2003) (1)
Editorial: Acute promyelocytic leukemia: An update (1991) (1)
Somatic Mutational Landscape of AML with Inv(16) and t(8;21) Identifies Two Distinct Patterns in Relapse Tumors (2014) (1)
MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study (2007) (1)
Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) (2012) (1)
Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia (2018) (1)
Classification and prognosis of acute lymphoblastic leukemia. (1981) (1)
Abstracts of workshop presentations (Part 5 of 13) (1985) (1)
Abstracts of workshop presentations (Part 16 of 16) (1987) (1)
Abstracts of workshop presentations (Part 6 of 13) (1985) (1)
The Non-Hodgkin Lymphoma Pathologic Classification Project (2020) (1)
FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients. (2006) (1)
Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. (2021) (1)
Abstracts of workshop presentations (Part 2 of 13) (1985) (1)
Patterns of relapse following chemotherapy in non-Hodgkin's lymphoma (1983) (1)
Abstract 5235: Identification of microRNA-3662as a novel tumor suppressor miR (2014) (1)
Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures, (2011) (1)
Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML). (2012) (1)
Severe renal tubular dysfunction during 5-azacytidine chemotherapy (1979) (1)
Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. (2009) (1)
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control (2018) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
Reply to K. Orendi et al. (2013) (1)
Abstract 2455: The long non-coding RNA (lncRNA)DANCRin acute myeloid leukemia (AML) stem cells (LSC) (2018) (1)
A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA) (2013) (1)
Dual Epigenetic Control of CCAAT/Enhancer Binding Protein α (C/EBPα) Expression in Acute Myeloid Leukemia. (2007) (1)
Publisher Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia (2020) (0)
Author Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia (2020) (0)
Result of curative radiation therapy in surgically staged Hodgkin's diseases: University of Minnesota experience from 1970 to 1975 (1977) (0)
Uniparental Disomies (UPD) of Chromosome 13q Is Associated with Shorter Disease-Free Survival in Adult Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2018) (0)
-mutated AML NPM1 Implications of the miR-10 family in chemotherapy response of (2014) (0)
50th Anniversary of Acta Haematologica (1998) (0)
Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia (2011) (0)
Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis (2020) (0)
arising in the setting of severe congenital neutropenia Distinct patterns of mutations occurring in de novo AML versus AML (2013) (0)
Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study. (2007) (0)
patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction (2002) (0)
Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML) (2011) (0)
Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC , ERG , and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples. (2009) (0)
Novel type of jumping translocation in a desmoid tumor (1995) (0)
PHENOTYPING AND PROPERTIES OF T AND B TUMORS1 (1982) (0)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia (2019) (0)
Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364 Value of Immunophenotype in Intensively Treated Adult Acute (2011) (0)
Abstract IA01: Clinical significance of molecular findings in acute myeloid leukemia. (2015) (0)
Glucocorticoid Receptors in Adult Acute Lymphoblastic Leukemia1 (2006) (0)
Contents, Vol. 46, 1987/ Title Page / Table of Contents (1987) (0)
High Resolution Array-Based CGH and SNP Studies of AML Genomes. (2007) (0)
Response to "A plea for prospective clinical trials by John D. Earle, M.D.". (1987) (0)
Abstracts of workshop presentations (Part 10 of 13) (1985) (0)
Curative radiation therapy of hodgkin's disease in surgically staged patients: university of minnesota experience (1977) (0)
Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720). (2007) (0)
The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts) (2016) (0)
Chromosomal Translocation Chromosomal Translocation Mechanisms and Consequences of Mechanisms and Consequences of (2006) (0)
The Lampe lecture. Radical radiation therapy in the treatment of laparotomy staged Hodgkin's disease patients. (1984) (0)
Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance) (2021) (0)
Detection of Microdeletions and Amplifications in Primary Human Acute Myeloid Leukemia (AML) Genomes Using Ultradense Oligomer Tiling Path Arrays and Comparative Genomic Hybridization (CGH). (2005) (0)
Molecular Landscape and Clinical Features of Acute Myeloid Leukemia (AML) with Complex Karyotype (CK) (2017) (0)
Prolonged S ingle-Agent V ersus C ombination C hemotherapy i n Indolent F ollicular L ymphomas: A S tudy o f t he C ancer a nd Leukemia G roup B (2003) (0)
A Combined Genetic Programming for Microarray Data Analysis (2020) (0)
Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance) (2019) (0)
THANKS TO REVIEWERS1999 (1999) (0)
Abstracts of workshop presentations (Part 8 of 13) (1985) (0)
Use of Monoclonal Antibodies, Morphology, and Cytochemistry to Probe the Cellular Heterogeneity of Acute Leukemia and Lymphoma1 (2006) (0)
Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia (2014) (0)
myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP (2013) (0)
Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations. (2004) (0)
Round Cell Liposarcoma With the Insertion (12;16)(ql3;pll.2pl3) (2015) (0)
CircPCMTD1: A Protein-Coding Circular RNA That Regulates DNA Synthesis in Leukemic Myeloblasts (2019) (0)
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics (2001) (0)
Effectiveness of chemotherapy for non-Hodgkin's lymphomas. (1975) (0)
Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (0)
Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations (2018) (0)
Abstract 1117: Dissection of the major hematopoietic quantitative trait locus in chromosome 6q23.3 identifies miR-3662 as a player in hematopoiesis and AML (2016) (0)
High resolution cytogenetic study of adipose tissue tumors: Localization of chromosome 12 breakpoints in lipoma to q15 and in myxoid liposarcoma to q13.3☆ (1993) (0)
EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML) (2016) (0)
Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma (2009) (0)
Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA (2018) (0)
Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia (2003) (0)
with standard-dose cytarabine a randomized trial comparing mitoxantrone and intermediate-dose cytarabine Postremission therapy in older patients with de novo acute myeloid leukemia: (2013) (0)
Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. (2010) (0)
MODELING and Targeting ERG -INDUCED Acute MYELOID LEUKEMIA (AML). (2009) (0)
Extended field radiation in non-Hodgkin's lymphoma (1978) (0)
Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols (2019) (0)
Treatment-inﬂuenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia (2012) (0)
Subject index Vol. 46, 1987 (1987) (0)
Mutation Patterns Identify Adult Patients with De Novo Acute Myeloid Leukemia (AML) Aged 60 Years or Older Who Respond Favorably to Standard Chemotherapy: an Analysis of Alliance Studies (2017) (0)
Subject index Vol. 40, 1985 (1985) (0)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. (2004) (0)
The long non-coding RNA HOXB-AS3 regulates ribosomal biogenesis in NPM1-mutated acute myeloid leukemia (2017) (0)
Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia (2021) (0)
Disease-Free Survival in Acute Nonlymphocytic Leukemia (2016) (0)
Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)
Abstract CT-06: The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression (2012) (0)
Acute promyelocytic leukemia: an update. (1991) (0)
Leukemia Group B Study 9511 improved outcomes in adult acute lymphoblastic leukemia: Cancer and Effective asparagine depletion with pegylated asparaginase results in (2013) (0)
Methotrexate vm 26 41 o demethyl 1 o 4 6 o 2 thenylidene beta d glucopyranosyl epi podophyllo toxin procarbazine and dexamethasone in the treatment of refractory lymphoma (1981) (0)
Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (Pts) with Presumably Sporadic De Novo Acute Myeloid Leukemia (AML) (2018) (0)
Abstract 519: The long non-coding RNA (lncRNA) HOXB-AS3 regulates transcription of ribosomal RNA (rRNA) in NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) (2018) (0)
Chromosomal abnormalities in acute leukemia. (1985) (0)
Importance of genetic heterogeneity in curing adult acute leukemia (AL). (2009) (0)
and whites with acute myeloid leukemia Differences in prognostic factors and outcomes in African Americans (2011) (0)
Author reply (0)
Importance of FLT3 Mutations and Other Genetic Abnormalities in Normal Karyotype AML. (2008) (0)
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy (2020) (0)
Book Review Innovative Leukemia and Lymphoma Therapy (Basic and Clinical Oncology. 35.) Edited by Gertjan J.L. Kaspers, Bertrand Coiffier, Michael C. Heinrich, and Elihu Estey. 598 pp., illustrated. New York, Informa Healthcare, 2008. $279.95. 978-0-8493-5083-2 (2009) (0)
MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2011) (0)
Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). (2009) (0)
asH members named Fellows of the american academy of arts and sciences (0)
t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. (2004) (0)
ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. (2005) (0)
Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23 (2005) (0)
CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22) (2016) (0)
Detection of Unique ALLÃ(cid:141) (MLL) Fusion Transcripts in Normal Human Bone Marrow and Blood: Distinct Origin of Normal versus Leukemic ALLÃ(cid:141) Fusion Transcripts1 (2006) (0)
Erratum: Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia (Cancer (2013) 119 (90-8)) (2014) (0)
Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2013) (0)
Abstract 1111: SyntheticmicroRNA (miR)-181ananoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML) (2012) (0)
Use of Bootstrapping to Evaluate Infrequent Genetic Abnormalities as Prognostic Factors for Survival in Human Acute Leukemias (1992) (0)
PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE) (2019) (0)
The Identification of ERG Related Pathways Pinpoints to Mechanisms Implicated in the Inferior Outcome of Acute T-Lymphoblastic Leukemia (T-ALL) with High ERG Expression. (2006) (0)
Non-Hodgkin's malignant lymphoma. (1979) (0)
reveal therapeutic targets in transgenic ERG myeloid leukemia Genome-scale expression and transcription factor binding profiles (2013) (0)
The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression (2019) (0)
Cancer and Leukemia Group B Studies in Acute Lymphoblastic Leukemia (1994) (0)
Curative radioteerapy in laparotomy-staged Hodgkin's disease, 15-year university of minnesota experience (1989) (0)
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (AML) (2019) (0)
A NUMBER OF recurring chromosome translocations (2011) (0)
B & T markers in leukemia and lymphoma. (1979) (0)
antibodies Adult acute lymphoblastic leukemia phenotypes defined by monoclonal (2011) (0)
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. (2012) (0)
Immunosuppression and Outcomes in Acute Myeloid Leukemia (2021) (0)
Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (2019) (0)
Acute leukemia. Modern management. (1974) (0)
Publisher Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia (2020) (0)
Gene Expression Profiles in Acute Myeloid Leukemia (AML): From Diagnosis to Prognosis. (2005) (0)
international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
ADVANCES IN LLM (2005) (0)
Geoffrey Peter Herzig, MD Leukemia Pioneer (1941–2013) (2014) (0)
Recurrent Genetic Variants of Long Non-Coding RNAs (lncRNAs) Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia (2017) (0)
Expression of a TGF-{beta} regulated cyclin-dependent kinase inhibitor in normal and immortalized airway epithelial cells (1995) (0)
Interview of Clara Derber Bloomfield by Olivia Wikle (2017) (0)
of chromosome 11 loci Novel methylation targets in de novo acute myeloid leukemia with prevalence (2010) (0)
Translocation (12;22)(q13;q12) is characteristic for clear cell sarcoma of tendons and aponeuroses (1993) (0)
In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease (2015) (0)
Elucidating the role of the long non-coding RNA dancr in leukemic stem cells in acute myeloid leukemia (AML) (2017) (0)
PF232 PROGNOSTIC IMPACT OF THE 2017 EUROPEAN LEUKEMIANET (ELN) CLASSIFICATION OF YOUNGER ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED ON CANCER AND LEUKEMIA GROUP B (CALGB)/ALLIANCE PROTOCOLS (2019) (0)
Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP (2012) (0)
Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B (2001) (0)
Micro RNA-3662 Located within the Major Hematopoietic Differentiation Quantitative Trait Locus on Chromosome 6q23 Acts As a Tumor Suppressor By Direct Targeting of the NF-ĸB Transcriptional Activation Pathway (2014) (0)
Identification of a new subgroup of adult acute T-lymphoblastic leukemia (T-ALL) with a very favorable outcome using low ERG and BAALC expression (2007) (0)
Reply to “Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases”. Haematologica 2014;99(2):e20–21. (2014) (0)
Abstracts of workshop presentations (Part 13 of 16) (1987) (0)
Defect in Acute Myeloid Leukemia with Trisomy 11 as a Recurrent Molecular ALL 1 Partial Tandem Duplication of Updated (2006) (0)
DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia (2019) (0)
Chromosomal Abnormalities in Acute Lymphoblastic Leukemia1 (1981) (0)
Abstract 1307: Heritable polymorphism predisposes to high expression ofBAALCin cytogenetically normal acute myeloid leukemia (CN-AML) (2012) (0)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (0)
E01 Biology, cytogenetics and molecular studies in acute myeloid leukemia (2007) (0)
Recognizing and evaluating non-Hodgkin's lymphomas. (1975) (0)
Neurofibromin 1 gene Mutations Are Recurrent Events in Adult Patients with Acute Myeloid Leukemia (AML), Associate with Poor Outcome and Refine the Adverse European Leukemianet (ELN) Risk Category (2017) (0)

This paper list is powered by the following services:

Other Resources About Clara D. Bloomfield

en.wikipedia.org

What Schools Are Affiliated With Clara D. Bloomfield?

Clara D. Bloomfield is affiliated with the following schools:

Clara D. Bloomfield's Academic­Influence.com Rankings